Tahini and Dermatitis in Breast Cancer

National Nutrition and Food Technology Institute50 enrolled

Overview

This study aimed to investigate the effect of tahini on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume tahini 48 gr per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Breast Cancer

Interventions

tahiniDIETARY_SUPPLEMENT

48 grams tahini

controlOTHER

no intervention

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women with Brest Cancer undergoing adjutant Radiation therapy Exclusion Criteria: * previous history of RT, MRM, * concomitant presence of two or more malignant tumors * metastasis to other areas * allergy or intolerance to tahini * skin diseases and wounds * severe liver and renal disease * autoimmune diseases * pregnant and lactating women * those who treated with hypo fraction RT

Outcomes

Primary Outcomes

severity of dermatitis

Change from Baseline severity at 4 weeks. The radiation dermatitis will be assessed according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.